These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 37035330)
1. CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases. Chevalier K; Genin M; Jean TP; Avouac J; Flipo RM; Georgin-Lavialle S; El Mahou S; Pertuiset E; Pham T; Servettaz A; Marotte H; Domont F; Chazerain P; Devaux M; Mekinian A; Sellam J; Fautrel B; Rouzaud D; Ebstein E; Costedoat-Chalumeau N; Richez C; Hachulla E; Mariette X; Seror R Front Med (Lausanne); 2023; 10():1152587. PubMed ID: 37035330 [TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics, Prognostic Factors, and Outcomes of COVID-19 in Autoimmune Rheumatic Disease Patients: A Retrospective Case-Control Study from Astana, Kazakhstan. Rutskaya-Moroshan K; Abisheva S; Abisheva A; Amangeldiyeva Z; Vinnik T; Batyrkhan T Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336418 [No Abstract] [Full Text] [Related]
3. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis. Shin JI; Kim SE; Lee MH; Kim MS; Lee SW; Park S; Shin YH; Yang JW; Song JM; Moon SY; Kim SY; Park Y; Suh DI; Yang JM; Cho SH; Jin HY; Hong SH; Won HH; Kronbichler A; Koyanagi A; Jacob L; Hwang J; Tizaoui K; Lee KH; Kim JH; Yon DK; Smith L Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3760-3770. PubMed ID: 35647859 [TBL] [Abstract][Full Text] [Related]
4. Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease. Shenoy P; Ahmed S; Shanoj KC; Shenoy V; Damodaran D; Menon AR; Alias B; SanjoSaijan ; Devakumar D; Babu ASS Clin Rheumatol; 2021 Nov; 40(11):4665-4670. PubMed ID: 34155573 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Avouac J; Drumez E; Hachulla E; Seror R; Georgin-Lavialle S; El Mahou S; Pertuiset E; Pham T; Marotte H; Servettaz A; Domont F; Chazerain P; Devaux M; Claudepierre P; Langlois V; Mekinian A; Maria ATJ; Banneville B; Fautrel B; Pouchot J; Thomas T; Flipo RM; Richez C; ; Lancet Rheumatol; 2021 Jun; 3(6):e419-e426. PubMed ID: 33786454 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19 : A Binational Cohort Study. Kim MS; Lee H; Lee SW; Kwon R; Rhee SY; Lee JA; Koyanagi A; Smith L; Fond G; Boyer L; Lee J; Rahmati M; Shin JY; Min C; Shin JI; Yon DK Ann Intern Med; 2024 Mar; 177(3):291-302. PubMed ID: 38437702 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Mortality Following SARS-CoV-2 Infection in Rural Versus Urban Dwellers With Autoimmune or Inflammatory Rheumatic Disease: A Retrospective Cohort Analysis From the National COVID Cohort Collaborative. Anzalone AJ; Jackson LE; Singh N; Danila MI; Reisher E; Patel RC; Singh JA; Arthritis Care Res (Hoboken); 2024 Aug; ():. PubMed ID: 39158165 [TBL] [Abstract][Full Text] [Related]
8. Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Nakafero G; Grainge MJ; Card T; Mallen CD; Nguyen Van-Tam JS; Williams HC; Abhishek A Rheumatology (Oxford); 2023 Apr; 62(4):1445-1450. PubMed ID: 36048896 [TBL] [Abstract][Full Text] [Related]
9. COVID-19 infection and efficacy of vaccination in patients with rheumatic diseases during Omicron outbreak in South Korea: a prospective cohort study. Kim YK; Kim JY; Jung JI; Park JK; Lee EY; Lee EB; Park JW RMD Open; 2023 Nov; 9(4):. PubMed ID: 37973535 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Risk Factors During First and Second Wave of COVID-19 in Patients with Autoimmune Rheumatic Diseases (AIRD): Results from KRACC Subset. Jain V; Shobha V; Kumar S; Janardana R; Selvam S Mediterr J Rheumatol; 2023 Sep; 34(3):342-348. PubMed ID: 37941863 [TBL] [Abstract][Full Text] [Related]
11. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 outcomes in patients with and without autoimmune rheumatic diseases: A multicenter comparative study. Abdulnaby NK; Gamal SM; Alkemary A; Abdo M; Sabry IM; Belita MI; Mohamed SS Int J Rheum Dis; 2023 May; 26(5):870-877. PubMed ID: 36929695 [TBL] [Abstract][Full Text] [Related]
13. Impact of COVID-19 Pandemic on Patients With Rheumatic Diseases in Medina, Saudi Arabia: An Observational Cross-Sectional Study. Safar Alsofyani I; Samman BS; Alhubayshi SS; Ellahi AT; Alsaedi AB; Almansour M Cureus; 2024 May; 16(5):e60128. PubMed ID: 38864060 [TBL] [Abstract][Full Text] [Related]
14. A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases. Patil A; Chanakya K; Shenoy P; Chandrashekara S; Haridas V; Kumar S; Daware M; Janardana R; Pinto B; Subramanian R; Nagaraj S; Singh YP; Singhai S; Jois R; Jain V; Srinivasa C; Dharmanand BG; Dharmapalaiah C; Sangeetha KN; Rao VK; Shobha V BMC Rheumatol; 2022 Jun; 6(1):32. PubMed ID: 35698182 [TBL] [Abstract][Full Text] [Related]
15. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Ann Rheum Dis; 2021 Apr; 80(4):527-538. PubMed ID: 33268442 [TBL] [Abstract][Full Text] [Related]
17. Autoimmune Rheumatic Diseases and Outcomes Following Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Ang SP; Chia JE; Misra K; Krittanawong C; Iglesias J; Gewirtz D; Mukherjee D Angiology; 2024 May; ():33197241255167. PubMed ID: 38771845 [TBL] [Abstract][Full Text] [Related]
18. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Freites Nuñez DD; Leon L; Mucientes A; Rodriguez-Rodriguez L; Font Urgelles J; Madrid García A; Colomer JI; Jover JA; Fernandez-Gutierrez B; Abasolo L Ann Rheum Dis; 2020 Nov; 79(11):1393-1399. PubMed ID: 32769150 [TBL] [Abstract][Full Text] [Related]
19. Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease. Van Doornum S; Bohensky M; Tacey MA; Brand CA; Sundararajan V; Wicks IP Arthritis Res Ther; 2015 Feb; 17(1):38. PubMed ID: 25879786 [TBL] [Abstract][Full Text] [Related]
20. Inflammatory rheumatic diseases developed after COVID-19 vaccination: presentation of a case series and review of the literature. Akkuzu G; Bes C; Özgür DS; Karaalioğlu B; Mutlu MY; Yıldırım F; Atagündüz P; Gündüz A; Soy M Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):2143-2151. PubMed ID: 36930514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]